<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="School of MedicineChicago, ILUnited States[], 8Environmental and Atmospheric Chemistry Laboratory," exact="Bangladesh" post="Atomic Energy CommissionDhakaBangladesh[], 9Department of Chemistry, The University of"/>
 <result pre="by: Alexander Rodriguez-Palacios, Case Western Reserve University School of Medicine," exact="United States" post="Reviewed by: Maria Stefanova Kamusheva, Medical University of Sofia,"/>
 <result pre="Medicine and Pharmacy, Romania; Ciprian Vasile Iovan, University of Oradea," exact="Romania" post="*Correspondence: William C. Cho williamcscho@gmail.com Daniela Calina calinadaniela@gmail.com Javad"/>
 <result pre="human coronavirus (SARS-CoV-2) seems emerged in December 2019 in Wuhan," exact="China" post="(1, 2). Later, on January 12, 2020, the World"/>
 <result pre="Antiviral for flu and Ebola RNA polymerase inhibitor Used in" exact="China" post="in patients of childbearing potential only if they had"/>
 <result pre="The camostat molecule, a synthetic serine protease inhibitor approved in" exact="Japan" post="for pancreatic diseases (which also have proteinases as pathogenic"/>
 <result pre="(Interferon beta) used in animal model studies (36, 45). Recently," exact="the US" post="Food and Drug Administration (FDA) has authorized the use"/>
 <result pre="from two studies involving remdesivir: The ACTT study, organized by" exact="the US" post="National Institute of Allergic and Infectious Diseases (NIAID) was"/>
 <result pre="study against the MERS virus, and the first study in" exact="China" post="against SARS-CoV-2 has been started. In addition, a team"/>
 <result pre="for influenza and Ebola infection. It was originally produced in" exact="Japan" post="and used more frequently in China; due to its"/>
 <result pre="more frequently in China; due to its teratogenic effect, in" exact="Japan" post="its use is only allowed during the evolution of"/>
 <result pre="individuals and for immunocompromised patients (65). Several countries, such as" exact="the United States" post="(66) and the United Kingdom (67), have announced initiatives"/>
 <result pre="and for immunocompromised patients (65). Several countries, such as the" exact="United States" post="(66) and the United Kingdom (67), have announced initiatives"/>
 <result pre="Several countries, such as the United States (66) and the" exact="United Kingdom" post="(67), have announced initiatives to treat patients hospitalized with"/>
 <result pre="COVID-19 MIRACLE is the first trial to have begun in" exact="China" post="against SARS-CoV-2. The combination of lopinavir/ritonavir protease inhibitors (marketed"/>
 <result pre="or without interferon beta), and remdesivir and chloroquine (or hydroxychloroquine)." exact="Spain" post="and Norway are the countries that have administered the"/>
 <result pre="interferon beta), and remdesivir and chloroquine (or hydroxychloroquine). Spain and" exact="Norway" post="are the countries that have administered the treatment, out"/>
 <result pre="the progress of the study; the first patients included in" exact="Norway" post="are part of the proposed cohort of 700 patients,"/>
 <result pre="by the National Institutes of Health1 and Medical Research in" exact="France" post="(Inserm), and it will include the same therapeutic molecules"/>
 <result pre="and a total of 3,200 patients from Belgium, Germany, Luxembourg," exact="the Netherlands," post="Spain, Sweden, and the United Kingdom. Several medical centers"/>
 <result pre="from Belgium, Germany, Luxembourg, the Netherlands, Spain, Sweden, and the" exact="United Kingdom." post="Several medical centers will start collecting data as new"/>
 <result pre="acceptable safety against SARS-COV-2 in multicenter clinical trials conducted in" exact="China" post="(74). The use of this drug appears in the"/>
 <result pre="by SARS-CoV-2 issued by the National Health Commission of the" exact="People's Republic of China." post="Another recent study suggested chloroquine phosphate tablet (500 mg"/>
 <result pre="SARS-CoV-2 issued by the National Health Commission of the People's" exact="Republic of" post="China. Another recent study suggested chloroquine phosphate tablet (500"/>
 <result pre="on respiratory viral loads was evaluated using SARS-COV-2 patients from" exact="France" post="(78). Hydroxychloroquine (600 mg daily) was administered to patients"/>
 <result pre="of umifenovir (an active antiviral against influenza, approved only in" exact="China" post="and Russia), its use in COVID-19 is promising; according"/>
 <result pre="having been active during the 2014 Ebola outbreak (93, 94)." exact="China" post="has already announced that it has a vaccine clinical"/>
 <result pre="is realized by the Military Academy of Medical Sciences of" exact="China" post="and Cansino Biologics and is based on a technological"/>
 <result pre="(COVID-19) became available. Janssen research teams, in collaboration with Beth" exact="Israel" post="Deaconess Medical Center, part of Harvard Medical School, have"/>
</results>
